BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

196 related articles for article (PubMed ID: 37230538)

  • 1. Anti-HVEM mAb therapy improves antitumoral immunity both in vitro and in vivo, in a novel transgenic mouse model expressing human HVEM and BTLA molecules challenged with HVEM expressing tumors.
    Demerlé C; Gorvel L; Mello M; Pastor S; Degos C; Zarubica A; Angelis F; Fiore F; Nunes JA; Malissen B; Greillier L; Guittard G; Luche H; Barlesi F; Olive D
    J Immunother Cancer; 2023 May; 11(5):. PubMed ID: 37230538
    [TBL] [Abstract][Full Text] [Related]  

  • 2. T cell intrinsic heterodimeric complexes between HVEM and BTLA determine receptivity to the surrounding microenvironment.
    Cheung TC; Oborne LM; Steinberg MW; Macauley MG; Fukuyama S; Sanjo H; D'Souza C; Norris PS; Pfeffer K; Murphy KM; Kronenberg M; Spear PG; Ware CF
    J Immunol; 2009 Dec; 183(11):7286-96. PubMed ID: 19915044
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A herpesvirus entry mediator mutein with selective agonist action for the inhibitory receptor B and T lymphocyte attenuator.
    Šedý JR; Balmert MO; Ware BC; Smith W; Nemčovičova I; Norris PS; Miller BR; Aivazian D; Ware CF
    J Biol Chem; 2017 Dec; 292(51):21060-21070. PubMed ID: 29061848
    [TBL] [Abstract][Full Text] [Related]  

  • 4. CD8 T cell memory to a viral pathogen requires trans cosignaling between HVEM and BTLA.
    Flynn R; Hutchinson T; Murphy KM; Ware CF; Croft M; Salek-Ardakani S
    PLoS One; 2013; 8(10):e77991. PubMed ID: 24205056
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The CD160, BTLA, LIGHT/HVEM pathway: a bidirectional switch regulating T-cell activation.
    Cai G; Freeman GJ
    Immunol Rev; 2009 May; 229(1):244-58. PubMed ID: 19426226
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Molecular basis for herpesvirus entry mediator recognition by the human immune inhibitory receptor CD160 and its relationship to the cosignaling molecules BTLA and LIGHT.
    Kojima R; Kajikawa M; Shiroishi M; Kuroki K; Maenaka K
    J Mol Biol; 2011 Nov; 413(4):762-72. PubMed ID: 21959263
    [TBL] [Abstract][Full Text] [Related]  

  • 7. BTLA interaction with HVEM expressed on CD8(+) T cells promotes survival and memory generation in response to a bacterial infection.
    Steinberg MW; Huang Y; Wang-Zhu Y; Ware CF; Cheroutre H; Kronenberg M
    PLoS One; 2013; 8(10):e77992. PubMed ID: 24205057
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Expression of anti-HVEM single-chain antibody on tumor cells induces tumor-specific immunity with long-term memory.
    Park JJ; Anand S; Zhao Y; Matsumura Y; Sakoda Y; Kuramasu A; Strome SE; Chen L; Tamada K
    Cancer Immunol Immunother; 2012 Feb; 61(2):203-214. PubMed ID: 21877247
    [TBL] [Abstract][Full Text] [Related]  

  • 9. BTLA inhibition has a dominant role in the
    Battin C; Leitner J; Waidhofer-Söllner P; Grabmeier-Pfistershammer K; Olive D; Steinberger P
    Front Immunol; 2022; 13():956694. PubMed ID: 36081508
    [TBL] [Abstract][Full Text] [Related]  

  • 10. CD160 inhibits activation of human CD4+ T cells through interaction with herpesvirus entry mediator.
    Cai G; Anumanthan A; Brown JA; Greenfield EA; Zhu B; Freeman GJ
    Nat Immunol; 2008 Feb; 9(2):176-85. PubMed ID: 18193050
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dual inhibition of BTLA and PD-1 can enhance therapeutic efficacy of paclitaxel on intraperitoneally disseminated tumors.
    Sun WZ; Lin HW; Chen WY; Chien CL; Lai YL; Chen J; Chen YL; Cheng WF
    J Immunother Cancer; 2023 Jul; 11(7):. PubMed ID: 37463789
    [TBL] [Abstract][Full Text] [Related]  

  • 12. CD160 isoforms and regulation of CD4 and CD8 T-cell responses.
    El-Far M; Pellerin C; Pilote L; Fortin JF; Lessard IA; Peretz Y; Wardrop E; Salois P; Bethell RC; Cordingley MG; Kukolj G
    J Transl Med; 2014 Sep; 12():217. PubMed ID: 25179432
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Monoclonal antibodies to B and T lymphocyte attenuator (BTLA) have no effect on in vitro B cell proliferation and act to inhibit in vitro T cell proliferation when presented in a cis, but not trans, format relative to the activating stimulus.
    Zhang M; Howard K; Winters A; Steavenson S; Anderson S; Smelt S; Doellgast G; Sheelo C; Stevens J; Kim H; Hamburger A; Sein A; Caughey DJ; Lee F; Hsu H; Siu G; Byrne FR
    Clin Exp Immunol; 2011 Jan; 163(1):77-87. PubMed ID: 21078085
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Regulatory T cell expression of herpesvirus entry mediator suppresses the function of B and T lymphocyte attenuator-positive effector T cells.
    Tao R; Wang L; Murphy KM; Fraser CC; Hancock WW
    J Immunol; 2008 May; 180(10):6649-55. PubMed ID: 18453584
    [TBL] [Abstract][Full Text] [Related]  

  • 15. CD160 activation by herpesvirus entry mediator augments inflammatory cytokine production and cytolytic function by NK cells.
    Šedý JR; Bjordahl RL; Bekiaris V; Macauley MG; Ware BC; Norris PS; Lurain NS; Benedict CA; Ware CF
    J Immunol; 2013 Jul; 191(2):828-36. PubMed ID: 23761635
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pathogenic Function of Herpesvirus Entry Mediator in Experimental Autoimmune Uveitis by Induction of Th1- and Th17-Type T Cell Responses.
    Sakoda Y; Nagai T; Murata S; Mizuno Y; Kurosawa H; Shoda H; Morishige N; Yanai R; Sonoda KH; Tamada K
    J Immunol; 2016 Apr; 196(7):2947-54. PubMed ID: 26912321
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Unconventional ligand activation of herpesvirus entry mediator signals cell survival.
    Cheung TC; Steinberg MW; Oborne LM; Macauley MG; Fukuyama S; Sanjo H; D'Souza C; Norris PS; Pfeffer K; Murphy KM; Kronenberg M; Spear PG; Ware CF
    Proc Natl Acad Sci U S A; 2009 Apr; 106(15):6244-9. PubMed ID: 19332782
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Modulation of T cell proliferation through the LIGHT-HVEM-BTLA cosignaling pathway.
    Cheung TC
    Recent Pat DNA Gene Seq; 2009; 3(3):177-82. PubMed ID: 19702559
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Detection of protein on BTLAlow cells and in vivo antibody-mediated down-modulation of BTLA on lymphoid and myeloid cells of C57BL/6 and BALB/c BTLA allelic variants.
    del Rio ML; Kaye J; Rodriguez-Barbosa JI
    Immunobiology; 2010 Jul; 215(7):570-8. PubMed ID: 19837478
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Therapeutic effects of B and T lymphocyte attenuator extracellular domain and heat shock protein 70 antigen peptide on cervical cancer in mouse model].
    Han LF; Qiu WM; Hu C; Wang L; Yao HX; Xiong SY; Meng M; Fang Y; Ma D
    Zhonghua Fu Chan Ke Za Zhi; 2010 Aug; 45(8):603-8. PubMed ID: 21029617
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.